ÂPfizer Announces Positive TopLine Results from Third Phase 3 Trial of Abrocitinib for Moderate to Severe Atopic Dermatitis Which Showed Improvements in Skin Clearance Disease Extent and Severity and Itch

ÂJADE COMPARE trial met all coprimary endpointsStudy included dupilumab in active control armSafety profile for abrocitinib consistent with previous studiesPfizer Inc. NYSEPFE announced today that JADE COMPARE B7451029 met its coprimary efficacy endpoints....